US DoJ Lets Biotechs Share Manufacturing Details To Speed Launch Of COVID-19 Therapies

 
• By Bowman Cox

Companies are shielded from antitrust concerns by Justice Department as they jointly prepare to manufacture whichever monoclonal-antibody-based coronavirus therapies emerge from development.

Sterile bottles and ampoules on the dispensing line.Sealed ampoules with medicine.Sterile capsules for injection. Bottles on the bottling line of the pharmaceutical plant.
they're coordinating, not colluding to deliver covid-19 therapies

More from Manufacturing

More from Compliance